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Recently, it has become clear that atherosclerosis is a chronic inﬂammatory disease in which inﬂammation and immune responses
play a key role. Accelerated atherosclerosis has been reported in patients with autoimmune diseases, suggesting an involvement
of autoimmune mechanisms in atherogenesis. Diﬀerent self-antigens or modiﬁed self-molecules have been identiﬁed as target of
humoral and cellular immune responses in patients with atherosclerotic disease. Oxidative stress, increasingly reported in these
patients,isthemajorevent causingstructuralmodiﬁcationofproteinswithconsequent appearance ofneoepitopes.Self-molecules
modiﬁedbyoxidativeeventscanbecometargetsofautoimmunereactions,thussustainingtheinﬂammatorymechanismsinvolved
in endothelial dysfunction and plaque development. In this paper, we will summarize the best characterized autoantigens in
atherosclerosis and their possible role in cardiovascular inﬂammation.
1.Introduction
Atherosclerosis was initially believed as a process caused by
the passive accumulation of lipids in the vessel wall. Recently,
however,ithasbecomeclearthatatherosclerosisisacomplex
condition and that multiple pathogenic factors contribute
to trigger and sustain vessel wall damage [1]. Experimental
studies have clearly demonstrated that atherosclerosis can
be considered a chronic inﬂammatory disease of the arterial
wall and that inﬂammation plays a key role in all stages of
the pathogenic process, including formation, progression,
and rupture of atherosclerotic plaque [2, 3]. In early lesions,
chemokines and adhesion molecules expressed by endothe-
lial cells recruit inﬂammatory cells, in particular monocytes
and T cells, to the arterial intima [4]. If the acute inﬂam-
matory response does not resolve and macrophages and T
cells continue to accumulate in the intima, a ﬁbrotic repair
process activates, leading to the formation of an atheroscle-
rotic lesion [5]. This process is driven by the inﬂammatory
cells that secrete cytokines and growth factors and stimulate
smooth muscle cells to migrate to the intima, where they
proliferate and produce extracellular matrix proteins [4]. In
theadvancedlesion,matrixmetalloproteinasessecretedfrom
activated macrophages degrade the connective tissue in the
ﬁbrous cap causing plaque rupture.
Accelerated atherosclerosis has been reported in patients
with various autoimmune diseases, suggesting an involve-
ment of autoimmune mechanisms in atherogenesis [6–9].
This phenomenon is attributed to the presence of traditional
risk factors for atherosclerosis, but could be also the result of
autoimmune and inﬂammatory mechanisms that are aggra-
vated in these diseases [6].
The ﬁrst evidence for the involvement of autoimmune
responses in atherosclerosis was provided by Jonasson et al.
[10] who demonstrated the expression of MHC class II
molecules and the presence of activated T cells in human
atherosclerotic plaques. Analysis of plaque-inﬁltrating T
cells revealed that these cells primarily showed the proin-
ﬂammatory Th1 phenotype [11]. Subsequent studies on
diﬀerent animal models demonstrated that activation of Th1
responses contributes to a more aggressive progression of
atherosclerosis [4]. Diﬀerent studies have strongly suggested
that atherosclerosis to some extent can be viewed as an
autoimmune disease in which the adaptive immune system2 International Journal of Inﬂammation
is targeted against self-antigens modiﬁed by biochemical
factors such as oxidative stress and hypercholesterolemia
[12]. In this respect, atherosclerosis shares some similari-
ties with other diseases characterized by an autoimmune
etiology, such as type I diabetes and rheumatoid arthritis.
In this contest, identifying the antigens responsible for the
activation of immune responses that promote and sustain
inﬂammation in atherosclerosis may be relevant.
2. Mechanisms of AutoimmunityGeneration
Although infectious agents have been associated with the
activation of immune mechanisms, evidence exist that
the main antigenic targets in atherosclerosis are modiﬁed
endogenous structures [12]. Atherosclerotic plaques express
autoantigens that are targeted by both IgM and IgG. It is
likely that these autoimmune responses initially have a ben-
eﬁcial eﬀect facilitating the removal of potentially harmful
antigens [13]. However, studies performed on hypercholes-
terolaemic mice deﬁcient in diﬀerent components of innate
and adaptive immunity uniformly indicate that the net eﬀect
of immune activation is proatherogenic [13, 14] and that
atherosclerosis, at least to some extent, should be regarded
as an autoimmune disease.
In general, three mechanisms have been proposed to
explain the autoimmune phenomena. (i) The molecular
mimicry theory proposes that the autoimmune response is
triggered by the initial activation of lymphocytes recognizing
epitopes derived from microorganisms that share sequence
homology with self-molecules. Therefore, autoimmunity
resulting from epitope mimicry may be a consequence of the
antipathogen immune response that can lead to disease in
predisposed individuals [15]. (ii) Impairments in apoptosis
execution and clearance can potentially render apoptotic
cells as a source of autoantigens normally sequestered in
the intracellular environment. Structural changes occurring
during cell death may inﬂuence the immunogenicity of
clusteredself-antigensatthesurfaceofapoptoticbodies[16].
(iii) Autoimmune responses may be directed against self-
structuresalteredbyhigh-aﬃnityligandbindingorbychem-
ical damage due to environmental events, such as oxidative
stress [17].
3. OxidativeStress in Atherosclerosis
Excessive oxidative stress and chronic inﬂammation are both
major characteristics of atherosclerosis [18, 19]. However,
the mechanisms by which oxidative stress mediates cardio-
vascular diseases are not clear [20]. Oxidative stress is the
major event causing protein structural modiﬁcation and
appearance of neo-/cryptic epitopes [21, 22]. Several systems
that generate reactive oxygen species (ROS) catalyze a variety
of oxidative damage to nucleic acids, lipids, and proteins
[23]. In physiological conditions oxidative stress is well
compensated. When there is an overproduction of ROS or a
deﬁciency of antioxidant enzyme activity, a biological dam-
age with vascular lesion formation and functional defects
may occur [24].
Oxidative stress and inﬂammation may determine the
modiﬁcation of self-structures also favouring the forma-
tion of advanced glycation end products (AGEs). Chronic
oxidative stress causes an accumulation of AGEs [25]. The
generation of AGEs and augmentation of proinﬂammatory
mechanisms in the vessel provide a potent feedback loop for
sustained oxidant stress, ongoing generation of AGEs, and
vascular perturbation.
Epidemiological studies have demonstrated an inverse
association between risk of stroke and intake of several
antioxidant-rich food items [26, 27]. Intake of high total
antioxidant capacity (the cumulative capacity of food com-
ponents to scavenge free radicals) has been related to
reducedinﬂammationandincreasedcirculatingantioxidants
in both cross-sectional and randomized intervention studies
[28, 29]. Nevertheless, clinical trials with anti-oxidants in
humans have shown conﬂicting results in protecting against
detrimental cardiovascular outcomes [20]. In particular,
most antioxidant vitamin trials have failed to reduce car-
diovascular morbidity and mortality [30]. In contrast, other
investigators sustain that the beneﬁcial eﬀects of lipid-
lowering and antihypertensive treatments are in part due to
their antioxidant properties [31, 32]. Furthermore, recent
ﬁndingssuggestthatantioxidantsmayplayaroleinreducing
the risk of cerebral infarction [33], thus conﬁrming the
pathogenetic role of oxidative stress in inﬂammation and
cardiovascular pathology. Collectively, these studies suggest
that more rigorous clinical trial designs are needed to
evaluate the usefulness of an antioxidant-based therapeutic
approach to cardiovascular diseases [34].
4. AutoantigensImplicatedin
CardiovascularDiseases
4.1. Oxidized Low-Density Lipoproteins. Oxidized low-densi-
ty lipoproteins (LDLs) is the best characterized autoantigen
in atherosclerosis. LDL modiﬁcations caused by oxidation
and enzymatic attacks result in the release of proinﬂamma-
tory phospholipids and lipid peroxides, which rapidly acti-
vate an inﬂammatory response in surrounding cells [35, 36].
Theoxidationprocessisalsoassociatedwithmajorstructural
modiﬁcations of LDL determining the formation of new
antigenic epitopes which can be presented by dendritic cells
and give rise to clonal expansion of oxidized LDL-speciﬁc
T cells [12]. About 10% of all T cells present in human
atherosclerotic plaques speciﬁcally recognize oxidized LDL
[17], and these cells are also present in the circulation [37].
Furthermore, autoantibodies speciﬁc for oxidized LDL have
been detected in humans and associated with cardiovascular
disease, but their role is controversial [38, 39]. Pilot studies
in animal models have provided promising results for the
development of vaccines based on oxidized LDL antigens
[12].
4.2. Heat Shock Proteins. A second category of autoantigens
that have been implicated in atherosclerosis are the stress-
induced heat shock proteins (HSPs) [40]. HSPs act as molec-
ular chaperons facilitating refolding of denatured proteinsInternational Journal of Inﬂammation 3
in stressed cells. Interestingly, some of them have also been
implicatedinloadingofimmunogenicpeptidestomajorhis-
tocompatibility class (MHC) I and II molecules [41]. Besides
being expressed in cells under physiological conditions,
HSPs increase in response to many environmental stresses,
includingoxidativestress[42].Understressconditions,HSPs
areexpressednotonlywithincells,butalsoonthecellsurface
and can be released into the intercellular space. Intracellular
HSPs have cytoprotective functions whereas extracellular
located or membrane-bound HSPs mediate immunological
functions [43]. In atherosclerotic lesions, human HSPs
appear to stimulate an immune response leading to the
development and progression of atherosclerosis [44, 45].
Antibody levels against HSP-60/65 are increased in subjects
with established cardiovascular disease and predict further
developmentofthedisease[46].Theseantibodiesspeciﬁcally
react with cells in atherosclerotic plaques and mediate lysis
of stressed endothelial cells and macrophages in vitro [47].
Recently, we demonstrated that human HSP90 is overex-
pressed in plaque and serum from patients with carotid
atherosclerosis and induces humoral and cellular immune
responses in these patients, implicating this self-protein as
a possible target autoantigen in the pathogenesis of carotid
atherosclerosis [48, 49]. In particular, we detected HSP90-
speciﬁc T lymphocytes within the atherosclerotic plaque;
these cells showed a predominant Th1, pro-inﬂammatory
proﬁle, suggesting a role for HSP90 in sustaining the inﬂam-
matory mechanisms responsible for the thrombogenicity of
the atherosclerotic lesion [49]. Major questions for future
research are the possible role of circulating anti-HSP90
antibodies and perhaps HSP90-speciﬁc peripheral blood T
cells as diagnostic and prognostic markers of disease.
4.3. Beta2-Glycoprotein I. Beta2-glycoprotein I (β2-GPI) is
a plasma protein involved in the haemostatic system that
has been detected in carotid atherosclerotic lesions. Previous
studies in animal models demonstrated that the transfer of
lymphocytes obtained from β2-GPI-immunized mice was
associated with the presence of larger fatty streaks within the
recipients compared with animals that received lymphocytes
from control mice, suggesting that T cells speciﬁc for β2-GPI
are capable to increase atherosclerosis and that β2-GPI is a
target autoantigen in this disease [6].
β2-GPI is also the most common target for antiphospho-
lipid antibodies (aPLs). These autoantibodies are associated
with thrombotic events and with the incidence of accelerated
atherosclerosis in patients with antiphospholipid antibody
syndrome and systemic lupus erythematosus [50–52]. In a
previous study, we observed that β2-GPI, as several plasma
proteins involved in the haemostatic system, undergoes
major structural and functional changes upon exposure to
oxidative stress and that such modiﬁcation renders this
self-molecule able to activate immature monocyte-derived
dendritic cells (DCs) [21]. We demonstrated that DCs stim-
ulated with the oxidized form of human β2-GPI presented
a mature phenotype, produced cytokines that support T-cell
activation, and were able to activate a Th1-type response by
allogenic na¨ ıve T cells, characterized by interferon (IFN)-γ
production. These ﬁndings are in accordance with our
recent study demonstrating that β2-GPI is a target antigen
of Th1 cellular immune response in patients with carotid
atherosclerosis [53]. In this study, we used the native form
of the plasma protein, but our previous evidence that β2-
GPI spontaneously undergoes oxidative modiﬁcation in in
vitro culture conditions [21] led us to hypothesize that T-cell
reactivitydetectedinthesepatientsisdirectedtotheoxidized
form of the protein.
More recently, we have demonstrated that a glycated
form of β2 - G P Ii sa b l et oa c t i v a t em o n o c y t e - d e r i v e di m m a -
ture DCs through RAGE engagement and to trigger a proin-
ﬂammatory signaling pathway mediated by the activation
of mitogen-activated protein kinases and nuclear factor-κB
[54].
Our ﬁndings underline the role of glycation/glycoxida-
tion in rendering this self-protein able to activate the
immune system and suggest that chronic activation of auto-
immune reactions against β2-GPI modiﬁed by oxidative
events may contribute to local and systemic inﬂammation,
thussustainingendothelialdysfunctionandpromotingthro-
mbotic events in patients with cardiovascular diseases.
4.4. Oxidized Haemoglobin. Microvascular haemorrhage in
atherosclerotic plaques is a common event in advanced
lesions [55]. Intraplaque haemorrhage is an event charac-
terizing high-risk “vulnerable” plaques, which are prone
to rupture and associated with acute thrombotic events.
Intraplaque haemorrhage causes the deposition of blood
products into the extravascular space, particularly red blood
cells (RBCs) and haemoglobin (Hb). In physiological con-
ditions, Hb released within the vascular compartment from
destroyed RBCs dimerizes and is rapidly bound by the
serum protein haptoglobin. The haptoglobin-Hb complex is
recognized by the scavenger receptor CD163 on the surface
of mononuclear phagocytes, that promotes endocytosis and
degradation of the complex [56]. Complicated plaques
are characterized by repetitive haemorrhage events and
hemolysis, accompanied with the release of large amounts of
Hb into the atherosclerotic lesions. In these conditions, the
capacityofHbscavengingmechanismsissaturated.Thepro-
inﬂammatory and pro-oxidant microenvironment within
the plaque may predispose free Hb to oxidative modiﬁca-
tions. Free Hb or its oxidized forms may represent dangerous
autoantigens, unwanted target of immune responses initially
directed to the removal of escaped or modiﬁed proteins.
Following this hypothesis, we have examined the presence
of T cells speciﬁc for oxidized Hb in the peripheral blood
of patients with advanced carotid atherosclerosis [57]. We
used an oxidized Hb preparation predominantly contain-
ing hemichromes. Hemichromes represent Hb oxidation
products characterized by a cross-linking between globin
and heme that is responsible for molecule distortion and
structural changes. We observed that the mean frequency of
IFN-γ-secreting T lymphocytes speciﬁc for oxidized Hb was
signiﬁcantly higher in patients with carotid atherosclerosis
than in healthy subjects, suggesting that the oxidized forms
of Hb display immunodominant T-cell epitopes that are able4 International Journal of Inﬂammation
to stimulate adaptive immunity. Furthermore, our oxidized
Hb preparation enhanced phenotypic maturation of LPS-
stimulated DCs, as demonstrated by the appearance of the
DC maturation marker CD83 and by the upregulation of
the costimulatory molecules CD80, CD40, HLA-DR, and
CD86, and signiﬁcantly increased the production of the pro-
inﬂammatory cytokines interleukin (IL)-12p70 and tumor
necrosis factor (TNF)-α by DCs [57]. In a more recent study,
we extended our results and demonstrated the presence
of T lymphocytes speciﬁc for oxidized Hb within human
atherosclerotic plaques. These cells produced high levels of
the pro-inﬂammatory Th1 cytokines IFN-γ and TNF-α [58].
Previous studies demonstrated that Hb exerts a pro-
inﬂammatory and oxidative action on endothelial cells [59,
60]. In particular, oxidized Hb upregulates the transcription
rate of several pro-inﬂammatory genes, that is, E-selectin,
ICAM-1,andVCAM-1,onvascularendothelialcellsthrough
the activation of the NF-κB family of transcription factors
[61]. Our data implicate oxidized Hb as a possible antigenic
target of cell-mediated immune responses contributing to
tissue damage in the pathogenesis of carotid atherosclero-
sis. We can hypothesize that intraplaque haemorrhage in
complicated lesions determines the release of large amounts
of free Hb. In these conditions, haptoglobin and CD163,
getting overwhelmed, are unable to clear eﬃciently the
protein which accumulates in the extracellular compartment
[55, 62]. The pro-oxidant microenvironment within the
atherosclerotic plaque may promote oxidative modiﬁcations
ofHbdeterminingthegenerationofnovelantigenicepitopes
on this self-molecule. These epitopes can activate speciﬁc T
lymphocytes with a predominant Th1 proﬁle that contribute
to inﬂammation. In physiological conditions, the oxidized
forms of Hb do not reach consistent levels in vivo because
oxidative stress is well compensated. Of note, we observed
the presence of T-cells speciﬁc for oxidized Hb also in the
peripheral blood from healthy subjects, suggesting that T cell
clones speciﬁc for this rare molecule are not deleted within
the thymus as, in basal conditions, they do not encounter the
target antigen necessary for their activation.
Overall, these results indicate that Hb, in particular con-
ditions, can sustain endothelial dysfunction interacting with
endothelial cells and/or with immune cells, thus promoting
the pathogenetic mechanisms involved in the progression of
cardiovascular diseases.
5. Conclusions
Excessive oxidative stress and low-grade chronic inﬂamma-
tion are major pathophysiological factors contributing to the
development of cardiovascular diseases. The strong oxidative
and inﬂammatory conditions occurring in patients with
atherosclerosis trigger the generation of a series of oxidation
byproducts that may contribute to the pathogenesis of the
disease. In addition to pro-inﬂammatory properties, self
molecules modiﬁed by oxidative events can become targets
of autoimmune reactions, thus sustaining the inﬂammatory
mechanisms involved in endothelial dysfunction and plaque
development (Figure 1). More studies aimed to clarify these
Oxidative stress
Inﬂammation
Self structures
Autoimmune responses
Cryptic or Neo
-
antigen expression
(ox-LDL, HSPs, beta2-GPI, Hb)
Endothelial dysfunction and atherosclerotic
disease progression
Figure 1: Schematic representation of the relationship between
oxidative stress and inﬂammation in cardiovascular diseases.
Patients with atherosclerosis are characterized by strong oxidative
stress conditions. Prooxidant compounds that form may interact
with molecular and cellular components thus determining expres-
sion of cryptic antigens, such as HSPs, and/or structural modiﬁca-
tions of self-molecules and generation of neoepitopes, such as oxi-
dized LDL. These cryptic or neoantigens may trigger autoimmune
reactions, thus sustaining the inﬂammatory mechanisms involved
in endothelial dysfunction and plaque progression. Of note, molec-
ular and cellular mediators of inﬂammatory mechanisms sustain
oxidative stress, thus creating a pathogenic system that ampliﬁes
itself. Ox-LDL: oxidized low-density lipoproteins; HSPs: heat shock
proteins; beta2-GPI: beta2-glycoprotein I; Hb: haemoglobin.
aspect might be useful for designing novel preventive strate-
gies in cardiovascular diseases. Modulation of the immune
system could represent a useful approach to prevent and/or
treat these diseases. A vaccination approach might be a
useful, eﬀective tool in the modern arsenal of cardiovascular
therapy and could possibly be used on a large scale at a
low cost. Several modalities of vaccines have been tested
against oxidized LDL, β2-GPI, HSPs, cholesterol, and other
molecules, with promising results. Nevertheless, a deeper
understanding of the role of immunization in atherosclerosis
will be essential to the use of vaccines in clinical medicine
[63, 64].
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